Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265187 | 0.90 | CYP2D6 (0.52) | CYP2D6CYP1A2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL2264882 | 0.90 | CYP2D6 (0.52) | CYP2D6CYP1A2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL5746020 | 0.88 | CYP2D6 (0.47) | CYP2D6CYP1A2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL5743947 | 0.87 | CYP2D6 (0.57) | CYP2D6CYP1A2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL5744694 | 0.85 | CYP2D6 (0.47) | CYP2D6CYP1A2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL11470495 | 0.81 | CYP2D6 (0.52) | CYP2D6CYP1A2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL5744645 | 0.81 | CYP2D6 (0.45) | CYP2D6CYP1A2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL70441 | 0.80 | CYP2D6 (0.46) | CYP2D6CYP1A2CYP3A4CYP2C19SLC6A9 | |
| SCHEMBL5745118 | 0.79 | CYP2D6 (0.50) | CYP2D6CYP1A2ALDH1A1CYP3A4CYP2C19 | |
| SCHEMBL5744749 | 0.79 | CYP2D6 (0.50) | CYP2D6CYP1A2ALDH1A1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. | 2016-07-07 | — | — | US | disclosed |
| EP-3033352-A1 | LINEAR PEPTIDE ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015023898-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015023898-A1 | LINEAR PEPTIDE ANTIBIOTCS | RQX PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| EP-1304329-B1 | Pyridonecarboxylic acid derivatives and their use as antibacterial agents | DAIICHI SANKYO CO LTD (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1288198-B1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-6992205-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2006-01-31 | — | — | US | disclosed |
| US-6864372-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2005-03-08 | — | — | US | disclosed |
| US-6794519-B2 | Process for the production of sulfonic esters | KANEKA CORPORATION (JP) | 2004-09-21 | — | — | US | disclosed |
| EP-1288198-A1 | PROCESS FOR THE PRODUCTION OF SULFONIC ESTERS | KANEKA CORPORATION (JP) | 2003-03-05 | — | — | EP | disclosed |
| EP-1019052-A4 | ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2001-05-16 | — | — | EP | disclosed |
| US-6214832-B1 | BENIGN PROSTATIC HYPERPLASIA | MERCK & CO., INC. | 2001-04-10 | — | — | US | disclosed |
| US-6143750-A | NITROGEN HETEROCYCLIC COMPOUNDS AS ENZYME INHIBITORS, FOR PROSTATE PROBLEMS AND MUSCLE RELAXANTS | MERCK & CO., INC. (US) | 2000-11-07 | — | — | US | disclosed |
| EP-1019052-A1 | ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1003512-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1998057642-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-12-23 | — | — | WO | disclosed |
| WO-1998057640-A1 | ALPHA 1A ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-12-23 | — | — | WO | disclosed |
| US-5849757-A | Pyridonecarboxylic acid derivatives substituted by a bicyclic amino group as antibacterials | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0807630-A1 | HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194358-A1 | LINEAR PEPTIDE ANTIBIOTCS | ANPEP, NPEPPS, PEPD | CYP2D6 4329/4885CYP1A2 4750/4885ALDH1A1 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.